Mepolizumab Reduced Asthma Attacks in Urban Youth
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma.
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma.
The FDA has issued an emergency use authorization for AstraZeneca’s Evusheld (tixagevimab and cilgavimab) to prevent COVID-19 in certain adults and children.
Levels of inflammatory cytokines in patients with severe asthma may predict responses to the monoclonal antibody benralizumab, a study in the Journal of Asthma suggests.
The US FDA has issued an EUA for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.
Read MoreThe FDA will review an sBLA for Dupixent (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
Read MoreThe first Phase 1 clinical trial of two monoclonal antibodies to treat Middle East respiratory syndrome coronavirus (MERS-CoV) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
Read MorePeople who have had evidence of a prior infection with SARS-CoV-2 appear to be well protected against being reinfected with the virus, at least for a few months.
Read MoreThe FDA authorized Eli Lilly and Co’s bamlanivimab and etesevimab, monoclonal antibodies for the treatment of mild to moderate COVID-19.
Read MorePregnant women infected with COVID-19 who were either asymptomatic or symptomatic passed SARS-CoV-2 antibodies to their newborns during pregnancy via the placenta.
Read MorePatients who recover from COVID-19 are protected against the virus for at least six months, and likely much longer, according to a study published in Nature by researchers at Rockefeller University.
Read MoreA new COVID-19 antibody assay was able to detect IgG and IgM antibodies to determine viable donor samples for therapeutic use and clinical trials.
Read MoreA Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy used for COVID-19.
Read MoreThe FDA issued an emergency use authorization for Regeneron’s casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in patients 12 and older.
Read MoreScientists have found that some people have antibodies against parts of their own immune system, allowing viruses to multiply rapidly.
Read MoreThe monoclonal antibody bamlanivimab reduced COVID-19-related hospitalization or ER visits in patients at high risk for disease progression within 28 days after treatment.
Read More